GSA Capital Partners LLP Acquires New Shares in UroGen Pharma Ltd. (NASDAQ:URGN)

GSA Capital Partners LLP acquired a new position in shares of UroGen Pharma Ltd. (NASDAQ:URGN) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 19,597 shares of the company’s stock, valued at approximately $249,000. GSA Capital Partners LLP owned 0.08% of UroGen Pharma as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. grew its stake in UroGen Pharma by 14.3% in the 1st quarter. Vanguard Group Inc. now owns 194,966 shares of the company’s stock valued at $2,924,000 after purchasing an additional 24,367 shares during the period. Price T Rowe Associates Inc. MD purchased a new stake in UroGen Pharma in the first quarter worth about $4,008,000. Tidal Investments LLC purchased a new stake in UroGen Pharma in the first quarter worth about $425,000. Oak Ridge Investments LLC increased its stake in shares of UroGen Pharma by 30.6% during the second quarter. Oak Ridge Investments LLC now owns 79,929 shares of the company’s stock valued at $1,341,000 after purchasing an additional 18,725 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of UroGen Pharma by 41.6% during the second quarter. Bank of New York Mellon Corp now owns 96,619 shares of the company’s stock valued at $1,621,000 after purchasing an additional 28,400 shares in the last quarter. 91.29% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on URGN. Guggenheim started coverage on UroGen Pharma in a report on Thursday, August 22nd. They issued a “buy” rating and a $40.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of UroGen Pharma in a report on Tuesday, October 15th. Oppenheimer reaffirmed an “outperform” rating and issued a $40.00 target price on shares of UroGen Pharma in a report on Wednesday, October 16th. Finally, EF Hutton Acquisition Co. I raised UroGen Pharma to a “strong-buy” rating in a research note on Monday, October 14th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, UroGen Pharma presently has a consensus rating of “Buy” and a consensus price target of $48.38.

UroGen Pharma Stock Up 3.1 %

Shares of NASDAQ URGN opened at $11.91 on Friday. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The firm has a market capitalization of $279.29 million, a price-to-earnings ratio of -3.78 and a beta of 1.12. The stock has a 50 day moving average price of $12.40 and a 200 day moving average price of $14.01. UroGen Pharma Ltd. has a 52-week low of $10.60 and a 52-week high of $20.70.

UroGen Pharma (NASDAQ:URGN) last posted its earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.29. The company had revenue of $25.20 million for the quarter, compared to analysts’ expectations of $24.22 million. During the same quarter in the prior year, the company earned ($0.68) EPS. Sell-side analysts expect that UroGen Pharma Ltd. will post -3.1 earnings per share for the current year.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.